Kornimate/medical-research-clean huggingface dataset:
arginine in treating patients with anti-vegf induced kidney injury

Conditions: Drug-Induced Nephropathy; Hypertension; Proteinuria

Summary: this phase ii trial studies how well arginine works in treating patients with kidney injury caused by anti-vegf drugs used in standard treatment for cancer. arginine is a nutritional supplement that may control side effects of anti-cancer drugs such as high blood pressure and protein in the urine and may also help to improve kidney function in patients.

primary objectives: i. to assess the value and/or limitations of using orally supplemented arginine (l-arginine) to improve renal function associated with the use of anti-angiogenic therapies that target vascular endothelial growth factor (vegf). outline: patients are randomized to 1 of 2 groups. group i: patients receive arginine orally (po) four times daily (qid). treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity. group ii: patience receive placebo po qid. treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity. after completion of study treatment patients are followed up within 1 month.

Eligibility criteria:
inclusion criteria: * on or enrolled for anti-vegf therapy * systolic blood pressure \>= 140 mm hg * diastolic blood pressure \>= 90 mm hg * proteinuria \>= 500 mg/day or worsening glomerular filtration rate (gfr) (\> 0.3 mg/dl in 48 hours \[hrs.\] or \> 50% decline from baseline creatinine in 1 week) exclusion criteria: * allergy to l-arginine * systolic blood pressure \< 140 mm hg * diastolic blood pressure \< 90 mm hg * proteinuria \< 500 mg/day * continuous tube feeds (since the medication will be given in-between meals)
long-term survival outcomes of total thyroidectomy and radioactive iodine therapy in unilateral t3/t4 ftc

Conditions: Follicular Thyroid Cancer; SEER Database Analysis

Summary: this study aims to thoroughly examine survival disparities in patients with t3 or t4 stage follicular thyroid carcinoma (ftc) as classified by the ajcc staging system. it compares outcomes between those who underwent total thyroidectomy (tt) and those who did not, and assesses the influence of radioactive iodine therapy (rait) on the survival of patients without tt. utilizing the seer database, a retrospective study identified patients diagnosed with t3 or t4 ftc, categorizing them into two cohorts: those treated with tt and those who were not (no-tt). the no-tt group was further analyzed to determine the impact of rait on patient survival. propensity score matching (psm) was applied to adjust for confounding variables. survival analysis, including kaplan-meier survival curves and landmark analysis, was conducted to evaluate the effects of surgical intervention and rait on overall survival (os) and cancer-specific survival (css).


Eligibility criteria:
inclusion criteria:1.the primary site code c73.9, denoting the thyroid gland;2.the international classification of diseases for oncology, third edition (icd-o-3) histology types comprising 8330 (follicular adenocarcinoma, nos), 8331 (follicular adenocarcinoma well differentiated), 8332 (follicular adenocarcinoma trabecular), 8335 (follicular carcinoma, minimally invasive), and 8339 (follicular thyroid carcinoma (ftc), encapsulated angioinvasive). exclusion criteria:(1). absence of t stage information or designation as t1, t2; (2). missing surgery codes; (3). cases not verified by histopathological analysis; (4). ftc not being the initial malignancy diagnosed in the patient; (5). unknown survival duration or survival less than one month; (6). presence of bilateral tumors.

Keywords: retrospective analysis, follicular thyroid carcinoma, total thyroidectomy, long-term survival outcomes.
canine-assisted anxiety reduction in emergency care

Conditions: Anxiety; Opioid Use; Children; Therapy Dog

Summary: compare the effect of a single exposure to a therapy dog and handler within the pediatric emergency department patient with anxiety by measuring the change in patient perception of anxiety before and after dog exposure using the faces scale. we will also measure galvanic skin response (resistance to electrical current).

this study challenges current dogma by introducing a widely available, low cost method of dog therapy to reduce patient stress. the organization "paws of love" estimates that it has 180,000 volunteers who have qualified therapy dogs and who are generally willing to volunteer their time in emergency care. the benefits may include improved perception of wellness, less opioid use, and decreased use of physical and chemical restraints. as a further extrapolation, this secondary effect may extend to improved patient-doctor communication and patient experience. this will in turn improve patient safety in the emergency department, decreasing the number of adverse events, and decreasing the risk of medical malpractice by improving the patient-provider relationship. (6, 7)

Eligibility criteria:
inclusion criteria: * 4-17 years old; * physician or nurse with primary care responsibilities believes that the patients has a moderate to high level of anxiety exclusion criteria: - violent behavior and any reported prior fear or adverse reaction to dogs in the dog intervention group.
prospective observational study on ustekinumab (stelara) assessing efficacy and healthcare resource utilization in crohn's disease

Conditions: Crohn Disease

Summary: the main purpose of this study is to assess ustekinumab's ability to induce clinical response and remission ("effectiveness") at week 16 and remission at week 52 and week 104 in participants with crohn's disease (cd). response and remission will be assessed using clinical parameters. retention rate at week 52 and 104 will also be studied.


Eligibility criteria:
inclusion criteria: * participant has a diagnosis of cd confirmed by investigator * participants with active cd who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic therapy or have medical contraindications to such therapies * the participant must sign informed consent before enrollment in the study. the consent form permits extraction of data from swibreg at baseline and during participation of the study and linkages to the patient registry (patientregistret), scb's registry usa for occupational details (longitudinell integrationsdatabas for sjukforsakrings- och arbetsmarknadsstudi er), the social insurance registry on long-term sick leave (forsakringskassans register gallande sjukskrivningar) and the prescription registry (lakemedelsregistret) * the participant must have been initiated on treatment with ustekinumab within the last 2 weeks (that is including those who already discontinued) or started on ustekinumab treatment less than (\<) 3 months ago if treatment start was documented in swibreg within 2 weeks of onset and has a record of harvey bradshaw index (hbi) when starting ustekinumab exclusion criteria: * the participant is enrolled in a clinical trial (randomized or non-randomized) in which the treatment of cd is dictated by a study protocol. if the participant is participating in another observational study (non-interventional), the participant may be included in this observational study * received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 60 days before the start of the study or the first data collection time point * participants who started ustekinumab despite contraindications for use * participants with planned stop of treatment with ustekinumab within 24 months from onset of treatment, that is bridging to other treatment or pregnancy planned
trial of hydrocortisone for post-traumatic stress disorder (ptsd)

Conditions: Post-traumatic Stress Disorder

Summary: developing novel and effective pharmacologic interventions for this post-traumatic stress disorder is important. the investigators propose to replicate findings of an earlier published pilot study using low dose hydrocortisone as a treatment for ptsd. in order to do so in a more meaningful way, the investigators will conduct a larger but similar randomized double-blind placebo-controlled, cross-over design treatment study examining the use of low dose hydrocortisone (or placebo) for 4 weeks in combat veterans suffering from ptsd. the investigators hypothesize that, as described by aerni et al. (2004), administration of daily hydrocortisone will lead to a reduction in ptsd symptom severity, but particularly for re-experiencing types (e.g., flashbacks, nightmares)of symptoms. the investigators also hope to examine potential predictors and moderators of treatment response based on subjects' clinical characteristics, as well as serum cortisol and acth levels.


Eligibility criteria:
inclusion criteria: * male military veterans * between the ages of 18-65 years old * generally good medical health with no clinically significant abnormalities on physical examination, electrocardiogram, or laboratory findings * ability to provide informed consent and comply with requirements of study protocol * no specific contraindications to hydrocortisone * clinically predominant dsm-iv diagnosis of ptsd * score of ≥ 40 on clinician administered ptsd scale \[caps\] exclusion criteria: * history of moderate to severe traumatic brain injury, seizure or organic mental illness * lifetime history of schizophrenia, bipolar disorder, other psychotic disorder, or depression with a score of ≥ 16 on the 17-item hamilton depression rating scale (hamilton, 1960), active suicidal ideation * unstable medical illness * subjects undergoing any formal psychotherapy within 3 months of enrollment * subjects that meet criteria for substance dependence during the last 6 months * history of adverse reaction to corticosteroids. * concurrent use of other psychotropic medication (e.g. benzodiazepines, antipsychotics)

Keywords: post-traumatic stress disorder ptsd cortisol hydrocortisone pharmacological treatment
left atrial enlargement: a crucial indicator for identifying atrial fibrillation in patients with hypertension

Conditions: Atrial Fibrillation; Hypertension,Essential; Left Atrial Dilatation

Summary: based on the data of inpatients with hypertension and a cross-sectional study with a large sample size, this study aims to find the early warning value of the left anteroposterior atrial diameter for the possible occurrence of atrial fibrillation in patients with hypertension, and compare the advantages and disadvantages of the above two methods for the early warning of the risk of atrial fibrillation in patients with hypertension, so as to achieve the purpose of early identification of high-risk groups that may develop atrial fibrillation.

background left atrial enlargement resulting from hypertension is closely linked to the development and persistence of atrial fibrillation (af). the newly proposed staging recognizes af as disease continuum, which makes us aware that af prevention should focus on the pre-af stage, and atrial enlargement is one of the important manifestations in this stage. previous scoring systems, such as cha2ds2-vasc and c2hest, along with the recently highlighted left atrial diameter (lad), have been significant tools for predicting af occurrence. however, a comprehensive assessment of their utility is currently lacking. purpose this study aims to explore the role of left atrial size in identifying atrial fibrillation (af) among hospitalized hypertensives, and to compare its recognition effectiveness with previous scoring systems. methods the investigators conducted a cross-sectional analysis within hospitalized hypertensives. the discovery, internal and external validation datasets were established. the extreme gradient boosting (xgboost) was employed to identify key variables related to af occurrence, which were ranked based on their importance scores. to gauge the predictive prowess of lad regarding af occurrence, the investigators plotted the receiver operating characteristic curve (roc) and calculated the area under the curve (auc). this enabled us to pinpoint the lad cutoff value corresponding to the maximum youden index, indicative of susceptibility to af. subsequently, youden index determined the optimal cutoff value from the roc curve. delong's test compared the identification abilities of different tools within the same dataset. logistic regression analysis assessed the correlation between clinical variables and left atrial size.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of primary hypertension using the current or past medical history. * availability of one or more complete ecg and 24h holter data. * availability of complete echocardiogram data in the current hospitalization. exclusion criteria: * patients under 18 years of age. * cases with incomplete or unidentifiable results from extracted data.
efficacy and safety assessment of t4090 ophthalmic solution versus rhopressa® ophthalmic solution in patients with open-angle glaucoma or ocular hypertension

Conditions: Glaucoma; Ocular Hypertension

Summary: the main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of t4090 (kinezodianone r hcl 0.2% and 0.3%) ophthalmic solution with rhopressa® ophthalmic solution


Eligibility criteria:
main inclusion criteria: * patient (male or female) ≥18 years old * patient with open angle glaucoma or ocular hypertension in both eyes * informed consent dated and signed. main exclusion criteria: * secondary open agle glaucoma (ex. pseudoexfoliation, pigmentary glaucoma) * advanced stage of glaucoma * history of ocular trauma, eye infection, or/and ocular clinically significant inflammation within the 6 previous months. * known or suspected hypersensitivity to one of the components of the imps or other product used in the clinical study * pregnancy (confirmed with a positive urine pregnancy test) or breast-feeding.
axial length change in eyes treated by silicone sponge scleral buckling

Conditions: Rhegmatogenous Retinal Detachment

Summary: all existing medical literatue regarding axial length (al) changes after scleral buckling surgery for retinal detachment, descibes changes after solid silicone buckling. in this hospital, the investigators use only silicone sponge buckling, which has different properties and a different buckle profile. there are no studies in the literature describing tha al changes after sponge buckling, or whether the al change is less or more than with solid silicone buckles. the investigators wish to determine whether the al change profile with their silicone sponge is significantly different, and if so, whether this is clinically important in determining the better choice of buckle material to be preferred.


Eligibility criteria:
inclusion criteria: * patients at least 6 months after succesful retinal detachment surgery * with silicone sponge scleral buckling * currently attached * with iol master pre-surgery axial length measurement exclusion criteria: * patients with failed surgery and currently detached * patients with vitreos silicone oil tamponade * patients with radial or other non-circumference buckles * patients with unclear media not amenable to iol master exam

Keywords: retinal detachment scleral buckle silicone sponge axial length surgery included silicone sponge scleral buckling retina currently attached at least 6 months after surgery
counseling older adults to control hypertension

Conditions: Hypertension; Vascular Diseases; Cardiovascular Diseases

Summary: this study will evaluate the effect of a senior center-based comprehensive therapeutic lifestyle intervention delivered through group-based counseling and motivational interviewing (mint-tlc) among 250 hypertensive african american or latino seniors age 60 and older in a randomized control trial.


Eligibility criteria:
inclusion criteria: * age 60 years or older * diagnosis of htn * taking at least one anti-hypertensive medication * self-identified black, african american, or latino exclusion criteria: * unable to comply with the study protocol * participation in other hypertension studies * severe hearing impairment * severe visual impairment * arm circumference \> 42 cm for large cuff, or arm circumference \> 52 cm for extra large cuff (if extra large cuff is available)

Keywords: hypertension older adults motivational interviewing lifestyle counseling senior centers
enterobius vermicularis infestation of the appendix

Conditions: Parasitic Disease

Summary: this study identifies the incidence of appendiceal enterobius vermicularis (e.v) infestation in all the patients undergoing appendectomy and evaluates the relationship between e.v infestation of the appendix and the acute appendicitis.

all the patients undergoing appendectomy surgical procedure for clinical picture of acute appendicitis in 3-years period at our referral hospital were evaluated to pick up the enterobius vermicularis infestation of the appendix. these cases were evaluated for clinico-laboratory characterization to define the incidence in our country and the relationship between the e.v and initiation of the the inflammatory process to study the possibility of limitation of surgical intervention in acute abdomen conditions.

Eligibility criteria:
inclusion criteria: all routine examined appendectomy specimens exclusion criteria: cases with clinical suspicion of tumor cases attached to the colectomy specimens
functional assessment of the patient with fibromyalgia and its relation to health: fibromyalgia and sarcopenia

Conditions: Fibromyalgia; Sarcopenia

Summary: fibromyalgia is a chronic syndrome that causes fatigue, sleep disorders and generalized chronic pain in different parts of the body. this pathology is more prevalent in women and is generally not attributed to any specific cause. this observational study aims to describe some important and health-related factors in patients with fibromyalgia. participants will have to fill out questionnaires related to sleep, anxiety, impact of the disease and sarcopenia index, and will then take tests related to grip strength for the upper limbs and dynamometry in the lower limbs. we will also employ the use of ultrasound to evaluate architectural measurements. last but not least, we cannot forget the pain measurements that are so necessary in this study population.

through the present research study we intend to analyze not only the health status of our sample but also to correlate the parameters analyzed with factors related to sarcopenia. through the data collection that will be carried out we can analyze variables as essential as pain, anxiety and depression, impact of the disease, agility, strength, anthropometric measurements, sleep and muscular architectural measurements by means of ultrasound in which we can analyze the fatty infiltration of structures such as the vastus lateralis, rectus anterior and vastus medius that allow us to obtain data that can define the characteristics of patients with fibromyalgia.

Eligibility criteria:
inclusion criteria: * diagnosed with fm * aged between 18 and 75 years * agree to participate and sign the informed consent. exclusion criteria: * who do not have recent surgeries * patients with reduced mobility * adequate level of comprehension to be able to answer the questionnaires that will be provided in the study.
ml-004 open-label extension study in adults and adolescents with autism spectrum disorders (asd)

Conditions: Autism Spectrum Disorder

Summary: ml-004-003 is a multi-center, open-label extension study that will enroll approximately 120 adolescent and adult subjects with asd that have completed study ml-004-002. the primary objective of the study will be to evaluate the safety of ml-004 in subjects with asd.


Eligibility criteria:
inclusion criteria: * has completed study ml-004-002 within the past 90 days * age 12 years to 46 years at screening * has a designated care/study partner who can reliably report on symptoms * has a diagnosis of autism spectrum disorder (asd) * has a body mass index (bmi) ≥18 kg/m² * psychoactive medications and adjunctive therapies stable for 4 weeks prior to screening * must be able to swallow study medication exclusion criteria: * has rett syndrome or child disintegrative disorder * history of epilepsy without current adequate control, or any seizure in the 6 months preceding screening * has a positive response to c-ssrs questions 4 and/or 5, or is a significant risk for suicidal behavior * has a clinical history of uncontrolled or severe hypertension * if female, is pregnant or lactating

Keywords: asd autism autism spectrum disorder social communication
progastrine colon depistage

Conditions: Colon Cancer Screening; Healthy Person

Summary: dosage of progastrin in asymptomatic person participating in colon cancer screening

for anyone who will participate in colon screening at the princess grace hospital of monaco and who has signed the informed consent document. a blood test will be performed in addition to the screening test to assess the rate of progastrin.

Eligibility criteria:
inclusion criteria: * participant in colon cancer screening * signing informed consent exclusion criteria: * any major medical, psychiatric or addictive illness that would affect the informed consent process * the consent of a representative is not allowed in this study

Keywords: progastrin screening bio-marker healthy person early stage
biomarkers in samples from patients with chronic lymphocytic leukemia treated on clinical trial ecog-2997

Conditions: Leukemia

Summary: rationale: studying samples of cells in the laboratory from patients with cancer may help identify biomarkers related to cancer. it may also help doctors learn how patients respond to treatment. purpose: this laboratory study is analyzing samples of cells from patients with chronic lymphocytic leukemia who were treated on clinical trial ecog-2997.

objectives: * to analyze the expression of a variety of informative molecules using a unique high-resolution flow cytometric immunophenotyping technology in samples from patients with chronic lymphocytic leukemia enrolled in clinical trial ecog-2997. outline: cell samples are analyzed for the following prognostic biomarkers: zap-70, phospho-syk, phospho-gsk-3β, phospho-akt, phospho-zap-70, cyclin d1, cyclin d2, p21cip1, phospho-reia, ikappabα, bax, mcl-1, pten, phospho-erk1/2, and phospho-mek1/2. biomarker signals are amplified using enzymatic amplification staining to obtain high resolution detection of cell-surface markers on leukemic cells. biomarker expression levels are measured using fluorescence activated cell sorting analysis. relationships between clinical outcomes, standard flow cytometric analysis, cytogenetic studies, and high resolution immunophenotyping will also be assessed.

Eligibility criteria:
disease characteristics: * stored frozen viable cells from patients with chronic lymphocytic leukemia treated on clinical trial ecog-2997 patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: chronic lymphocytic leukemia